Phioanh Nghiemphu is a Neurology physician. OpenAlex indexes 335 publications with 12,162 citations (h-index 57); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
300 Medical Plaza
#b200
Los Angeles, CA 900950001
Telephone
310-794-1195Provider last certified this registry record 23 Jan 2020.
Clinical trials
- ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
Sponsor: Jonsson Comprehensive Cancer Center
- Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Sponsor: Jonsson Comprehensive Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- SpringWorks Therapeutics, Inc.Program year202571 payments$72,519openpaymentsdata.cms.gov ↗
- Alexion Pharmaceuticals, Inc.Program year202511 payments$15,265openpaymentsdata.cms.gov ↗
- Day One BiopharmaceuticalsProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma
Journal of Clinical Oncology
2024 - NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022
Journal of the National Comprehensive Cancer Network
2023 - The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma
Proceedings of the National Academy of Sciences
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”